Hasten, a biopharmaceutical company, agreed to acquire non-core assets from Takeda, a pharmaceutical company in Asia, for $322m. “China is an important market for Takeda in our efforts to accelerate the availability of our highly innovative medicines to patients living with complex and rare diseases. This sale will further sharpen Takeda’s focus and resources in fast tracking innovation in China, and the Emerging Markets. At the same time, we are confident that under Ray Capital, Hasten will be well-positioned to provide continued patient access to these trusted products in China," Ricardo Marek, Takeda President, Growth & Emerging Markets Business Unit.